According to a new report published this month (Global Antibody Drug Conjugate Market Outlook 2018) the ADC market is anticipated to reach US$ 3.45 Billion by 2018. In the reports market analysts review the market for brentuximab vedotin (Adcetris®; Seattle Gentics) and ado-trastuzumab emtansine (Kadcyla®; Genentech/Roche) in detail. Market potential for these drugs has been estimated keeping in mind the fact that these drugs are being tested in clinical trials for various indications apart from the ones for which they have already been approved. These drugs will take some time in order to capture their entire potential market.
The report also provides an insight into the key ADCs that are currently in pipeline. At present, only one drug, Inotuzumab Ozogamicin (CMC 544; Pfizer) is in late stage clinical trial. Apart from new drug candidates, previously approved drugs are also in late stage trials for other indications. Later in the report, strategic activities such as mergers, acquisitions and collaborations that have taken place over ADC have been provided. These activities are aimed at combining technologies and capabilities of other companies with inherent ones for the development of ADCs.
Major drivers such as advances in linker technology and patent fencing through ADC development are discussed in the report. In an attempt to protect their innovative blockbuster drugs, many pharma giants are moving towards ADCs. These moves are going to have a major impact in shaping the ADC market in the coming years. On the other hand, challenges such as the high cost of production of ADCs; difficult upstream and downstream processing; safety considerations etc., will have to be taken care of.
The analysts also discuss major players of the ADC market. A brief business overview of every player is provided along with their product and pipeline portfolio and recent developments. Finally, the report includes a comparative strength and weakness analysis of the major players. Overall, the report is designed to be a complete source with analysis for clients and potential investors.
Published in: Research and Markets website
